LONDON (Reuters) - Britain's healthcare cost watchdog NICE said on Friday it was not able to recommend a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, and has asked for more information from the companies.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment